Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Depreciation and Depletion (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Depreciation and Depletion for 13 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion changed 0.0% to $100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Dec 2025, down 40.0% year-over-year, with the annual reading at $200000.0 for FY2025, 77.78% down from the prior year.
  • Depreciation and Depletion for Q4 2025 was $100000.0 at Aytu Biopharma, roughly flat from $100000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $500000.0 in Q2 2021, with the low at $100000.0 in Q2 2024.
  • Average Depreciation and Depletion over 5 years is $266666.7, with a median of $300000.0 recorded in 2022.
  • The sharpest move saw Depreciation and Depletion soared 2122.22% in 2021, then plummeted 66.67% in 2024.
  • Over 5 years, Depreciation and Depletion stood at $400000.0 in 2021, then changed by 0.0% to $400000.0 in 2022, then decreased by 25.0% to $300000.0 in 2023, then tumbled by 66.67% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $100000.0, $100000.0, and $100000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.